CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Clarus Therapeutics Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Clarus Therapeutics Holdings Inc
355 S. Grand Avenue, Suite 1450
Phone: (847) 562-4300p:847 562-4300 LOS ANGELES, CA  90071  United States Fax: (302) 636-5454f:302 636-5454
This company's Plan of Liquidation went into effect on 2/28/2023
This company ceased filing statements with the SEC on 3/1/2023.
This company is no longer actively traded on any major stock exchange.
Business Summary
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company. The Company is engaged in the development of androgen-based medicines. The Company is focused on the commercialization of JATENZO, which is an oral testosterone replacement or testosterone replacement therapy (TRT). JATENZO is a created by the linkage of T with the fatty acid undecanoic acid to form testosterone undecanoate. JATENZO is developed for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. It also focuses on the signs and symptoms associated with hypogonadism such as psychosexual symptoms, body mass index, fat mass and bone mineral density. The Company’s subsidiary is Clarus Therapeutics, Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202212/31/2021YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
6770 Blank checks
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Restructuring Officer Lawrence R.Perkins 45 9/5/2022 9/5/2022

Subsidiaries
Business Name Address City State/Province Country
Clarus Therapeutics Inc. 555 Skokie Blvd Ste 340 Northbrook IL United States

Business Names
Business Name
BLUW
BLUWU
Clarus Therapeutics Inc.
Clarus Therapeutics, Inc.
CRXT
CRXTQ

General Information
Outstanding Shares: 52,020,731 (As of 8/31/2022)
Shareholders: 27
Stock Exchange: OTC
Federal Tax Id: 851231852
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, November 17, 2024